Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine
File(s)
Accepted version
Author(s)
Screaton, G
Mongkolsapaya, J
Type
Journal Article
Abstract
A dengue vaccine has been pursued for more than 50 years and, unlike other flaviviral vaccines such as that against yellow fever, progress has been slow. In this review, we describe progress toward the first licensed dengue vaccine Dengvaxia, which does not give complete protection against disease. The antibody response to the dengue virion is reviewed, highlighting immunodominant yet poorly neutralizing responses in the context of a highly dynamic structurally flexible dengue virus particle. Finally, we review recent evidence for cross-reactivity between antibody responses to Zika and dengue viruses, which may further complicate the development of broadly protective dengue virus vaccines.
Date Issued
2018-06-01
Date Acceptance
2017-07-17
Citation
Cold Spring Harbor perspectives in biology, 2018, 10 (6)
ISSN
1943-0264
Publisher
Cold Spring Harbor Laboratory Press
Journal / Book Title
Cold Spring Harbor perspectives in biology
Volume
10
Issue
6
Copyright Statement
© 2017 Cold Spring Harbor Laboratory Press; all rights reserved
Identifier
PII: cshperspect.a029520
Publication Status
Published
Date Publish Online
2017-07-17